1,721,509 research outputs found
Low molecular weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a metanalysis.
No full textRisk scores for death in patients with cancer-related venous thromboembolism. still a long road ahead
No full textPatients with cancer have an increased risk of venous thromboembolism (VTE) compared with non-cancer patients.1 In these patients, the risk of VTE is variable and seems to be related to several factors including cancer site and extension, anti-cancer treatment and several intrinsic patient characteristics.2,3 Low-molecular-weight heparin (LMWH) has been for many years the treatment of choice for cancer-related VTE. The European Society of Cardiology (ESC) guidelines published in 2019 opened to the use of direct oral anticoagulants (DOACs) for treatment of cancerrelated VTE.
Ten questions on venous thromboembolism
No full textVenous thromboembolism (VTE), which includes pulmonary embolism and deep vein thrombosis, is a leading cause of morbidity and mortality worldwide. Based on new evidence, the management and treatment of VTE have changed over the years. For several decades, low molecular weight heparin and vitamin K antagonists have been the two cornerstones of anticoagulant therapy for VTE. Recently, the introduction in clinical practice of the new oral anticoagulants has radically changed the management of VTE for their easy use and their better efficacy and safety profile. Here, we report on recent evidence of 10 still controversial clinical questions concerning common diagnostic and therapeutic aspects of VTE
Solutions to reduce cardiovascular events in patients with atrial fibrillation
No full textAF is the most common sustained cardiac rhythm disorder and an established risk factor for ischemic stroke. Ischemic strokes which occur in patients with AF are particularly severe and disabling. In addition, stroke recurrence is more common in patients with AF compared with those without it. Previous cerebrovascular events, age, hypertension, diabetes, and heart failure are risk factors for stroke in patients with AF.
Various risk stratification schemes have been developed to quantify the risk for stroke in patients with AF. Currently, the most frequently used schemes to assess stroke risk in patients with AF are CHADS2, the ACC/AHA/ESC and American College of Chest Physicians (ACCP) schemes.
Current risk scores are largely derived from risk factors identified from clinical trials and many potential risk factors have not been properly considered. Consequently, the stroke risk in many patients could be underestimated, and these patients could receive a suboptimal antithrombotic prophylaxis.
There is substantial evidence for the benefit of vitamin K antagonists (VKA) in preventing stroke and reducing mortality. Novel oral anticoagulants are available for stroke prevention in patients with AF which overcome some of the difficulties associated with VKA. The introduction of novel oral anticoagulants in clinical practice and the advances in identifying patients at risk of stroke together may overcome many of the difficulties in providing effective stroke prevention for patients with AF.AF is the most common sustained cardiac rhythm disorder and an established risk factor for ischemic stroke. Ischemic strokes which occur in patients with AF are particularly severe and disabling. In addition, stroke recurrence is more common in patients with AF compared with those without it. Previous cerebrovascular events, age, hypertension, diabetes, and heart failure are risk factors for stroke in patients with AF. Various risk stratification schemes have been developed to quantify the risk for stroke in patients with AF. Currently, the most frequently used schemes to assess stroke risk in patients with AF are CHADS2, the ACC/AHA/ESC and American College of Chest Physicians (ACCP) schemes. Current risk scores are largely derived from risk factors identified from clinical trials and many potential risk factors have not been properly considered. Consequently, the stroke risk in many patients could be underestimated, and these patients could receive a suboptimal antithrombotic prophyl..
Venous thromboembolism and COVID-19: Mind the gap between clinical epidemiology and patient management
No full text
Handbook on cerebral venous thrombosis
No full textCerebral veins contain about 70% of the total cerebral blood volume, but cerebral venous thrombosis (CVT) occurs about a thousand times less often than arterial stroke. CVT affects mostly young adults and children, and in about one quarter of cases the cause remains unknown. Written by international experts, this publication is dealing with epidemiology, risk factors, coagulation disorders, clinical presentation especially focusing on headache, current neuroradiological treatment, complications and long-term prognosis of CVT. The book covers the full spectrum of CVT pathogenesis and offers a new and effective approach to improve earlier diagnosis, recognize new risk factors and to identify the most severe manifestations, which require more aggressive treatments. Neurologists, interventional neuroradiologists, neurosurgeons, and all physicians who are involved in the care of patients with CVT will welcome this publication as a useful and up-to-date clinical guide
Prevention of venous thromboembolism after acute spinal cord injury with low-dose heparin or low-molecular-weight heparin.
No full text
- …
